BeiGene (06160) shares climbed more than 3% in morning trading. As of press time, the stock was up 2.86% at HK$259, with turnover of HK$451 million.
On the news front, on November 5, BeiGene released its financial results, reporting revenue of RMB 34.993 billion for the first three quarters, up 26.8% year-on-year, while profit reached RMB 6.055 billion, soaring 431.8% year-on-year.
Buoyed by its strong performance in the first three quarters, BeiGene announced it has once again raised its operating performance forecast for the 2026 fiscal year, adjusting its full-year revenue guidance from "RMB 44.9 billion to RMB 46.2 billion" to a range of "RMB 46.3 billion to RMB 47 billion." Notably, this marks the company's third upward revision of its full-year guidance this year.
According to CITIC Securities, in the hematology oncology space, BRUKINSA's continued volume growth, the approval of new indications for sonrotoclax, and the potential filing of a marketing application for BTK CDAC together form multiple growth drivers. In the solid tumor space, core assets such as CDK4 inhibitors, B7-H4 ADCs, and GPC3 bispecific antibodies are densely entering Phase III registrational clinical trials, indicating a clear medium- to long-term growth trajectory. In our view, the company's fundamental performance continues to strengthen, and its innovation pipeline is about to enter a period of fruition, and we maintain a "Buy" rating.
Comments